



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/771,552

02/03/2004

Leonard Bell

ALXN-PO1-114

6183

28120 7590 02/26/2007

FISH & NEAVE IP GROUP
ROPES & GRAY LLP
ONE INTERNATIONAL PLACE
BOSTON, MA 02110-2624

EXAMINER

VANDERVEGT, FRANCOIS P

ART UNIT

PAPER NUMBER

1644

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
--	-----------	---------------

3 MONTHS

02/26/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary	Application No. 10/771,552	Applicant(s) BELL ET AL.	
	Examiner F. Pierre VanderVegt	Art Unit 1644	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 24 November 2006.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-171 is/are pending in the application.
- 4a) Of the above claim(s) 1-108 and 121-171 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 109-120 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date <u>20050523, 20060824, 20061124</u> . | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1644

DETAILED ACTION

The instant application, filed on February 3, 2004, does not claim priority to any earlier application.

Claims 1-171 are currently pending.

Election/Restrictions

1. Applicant's election without traverse of Group VI, claims 109-120, in the reply filed on November 24, 2006 is acknowledged.
2. Claims 1-108 and 121-171 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on November 24, 2006.

Accordingly, claims 109-120 are the subject of examination in the present Office Action..

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

3. Claims 109-120 are rejected under 35 U.S.C. 103(a) as being unpatentable over Vakeva et al (Circulation [1998] 97:2259-2267; U on form PTO-892) in view of Reiter et al (Nature Medicine [2002] 8(12):1383-1389; V on form PTO-892) and Fitch et al (Circulation [1999] 100:2499-2506; CA cited on form PTO-1449 filed 08/24/2006), as evidenced by Claque et al (Biomed. Instrum. Technol. [1995] 29(5):419-424, Abstract only; W on form PTO-892).

The claims are drawn to the treatment of nitric oxide deficiency in a subject having a hemolytic disease. Vakeva teaches that subjects who undergo prolonged periods of myocardial ischemia experience tissue injury and cell death (Abstract and page 2259, column 1 in particular). Vakeva relates the damage to activated terminal complement components (Abstract in particular). Vakeva teaches that treatment with an anti-C5 antibody inhibits apoptosis and necrosis and blocks greater than 80% of serum hemolytic activity (Abstract, Figure 8, section bridging pages 2265-2266 and paragraph bridging 2264-2265 in particular).

Reiter teaches that cell-free hemoglobin in sickle cell disease limits the availability of nitric oxide (NO)(Abstract in particular). Reiter teaches that free hemoglobin in the serum binds to NO 1,000 more rapidly than hemoglobin sequestered in erythrocytes. Reiter teaches that NO can only reach levels needed for activating guanylyl cyclase in smooth muscle to cause vasodilation only when hemoglobin is sequestered in erythrocytes (page 1383, column 1 in particular). Reiter further teaches that this condition in sickle cell is similar to that seen in clinical diseases such as hemolysis during cardiopulmonary bypass procedures (page 1387, column 2 in particular).

Fitch teaches that coronary bypass surgery (CBP) elicits a systemic inflammatory response (page 2499, column 1 in particular). Fitch teaches a method of administering of a humanized single chain monoclonal antibody directed to human complement component C5 (h5G1.1-scFv) to subjects undergoing CBP. The h5G1.1-scFv antibody is a complement inhibitor that binds to complement component C5 and prevents the cleavage of C5 into C5a and C5b (Fitch page 2500, column 1 in particular). Fitch teaches that h5G1.1-scFv treatment inhibited pathological complement activation, had a pronounced anti-inflammatory effect, and was associated with a significant reduction in myocardial injury and blood loss (page 2504, column 2 in particular). Blood loss in bypass procedures is known to be associated with hemolysis, as evidenced by Claque (Abstract in particular). Based upon the teachings of Fitch in light of the teachings of Reiter, the artisan would recognize that this may be due to the reduced capacity for vasodilation due to the lack of NO caused by free hemoglobin resulting from hemolysis.

It would have been prima facie obvious to a person having ordinary skill in the art at the time the invention was made to treat subjects experience hemolytic disease as a result of coronary bypass surgery for nitric oxide deficiency using the anti-C5 antibody h5G1.1-scFv. One would have been motivated to combine the teachings with a reasonable expectation of success by the teachings of Vakeva that treatment of ischemia with anti-C5 antibody greatly reduced hemolysis, the teachings of Reiter that free hemoglobin resulting from hemolysis during cardiopulmonary bypass procedures greatly reduces NO levels in serum

Art Unit: 1644

and the teachings of Fitch that treatment of bypass patients with h5G1.1-scFv antibody reduced cell injury and blood loss.

Claims 112-114 are included because, while the references are silent about the proportion of type III red blood cells, silence about a particular property does not necessarily constitute absence of that property. Also, claims 115-117 are included because, while the references are silent about the platelet counts in a subject, silence about a particular property does not necessarily constitute absence of that property. Furthermore claims 118-120 are included because, while the references are silent about the reticulocyte counts in a subject, silence about a particular property does not necessarily constitute absence of that property. The office does not have the facilities and resources to provide the factual evidence needed in order to establish that there is a difference between the materials, i.e., that the claims are directed to new materials and that such a difference would have been considered unexpected by one of ordinary skill in the art, that is, the claimed subject matter, if new, is unobvious. In the absence of evidence to the contrary, the burden is on the Applicant to prove that the claimed materials are different from those taught by the prior art and to establish patentable differences. See *In re Best* 562F.2d 1252, 195 USPQ 430 (CCPA 1977) and *Ex parte Gray* 10 USPQ 2d 1922 (PTO Bd. Pat. App. & Int. 1989).

Conclusion


4. No claim is allowed.


5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to F. Pierre VanderVegt whose telephone number is (571) 272-0852. The examiner can normally be reached on M-Th 6:30-4:00 and Alternate Fridays 6:30-3:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1644

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

F. Pierre VanderVegt, Ph.D. 
Patent Examiner
February 20, 2007



DAVID A. SAUNDERS
PRIMARY EXAMINER